What is VivoSim Labs Inc's earnings per share (EPS)?

VivoSim Labs Inc (VIVS) reported diluted earnings per share of -$5.35 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

VivoSim Labs Inc Financials

VIVS

Trailing 12 months to June 30, 2026

Revenue $112K -21.1% YoY

Net Income -$12.3M -520.9% YoY

EPS (Diluted) -$4.47 YoY not available

Free Cash Flow -$10.1M +3.0% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE March

VivoSim Labs Inc (VIVS) reported $112K in revenue over the twelve months to Jun 30, 2026, down 21.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VIVS FY2026 2026-08-29

Development-stage economics dominate VivoSim Labs, with recurring cash needs funded externally while equity turns negative.

In FY2026, R&D spending of $4.2M dwarfed revenue of $131K, showing that reported activity remains development-led rather than a scaled selling model. Operating cash flow of -$10.8M broadly tracked the net loss of -$13.8M, indicating that losses are translating into cash needs rather than arising mainly from non-cash accounting charges.

The cost structure is dominated by operating effort: FY2026 operating loss was -$11.5M while capital expenditures were $0, meaning cash consumption is expense-led rather than tied to heavy physical reinvestment.

Liabilities of $8.5M exceeded assets of $7.4M, leaving equity negative. The financing inflow of $4.4M was still smaller than operating cash flow of -$10.8M, so external funding did not offset the period's operating need.

Financial Health Signals

Financial health score not available

VivoSim Labs Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-71.69

VivoSim Labs Inc scores -71.69, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.9M) relative to total liabilities ($8.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

VivoSim Labs Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

VivoSim Labs Inc reported a net loss of $13.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

VivoSim Labs Inc reported an operating loss of $11.5M against $12K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$131K

YoY-9.0%

10Y CAGR-21.5%

VivoSim Labs Inc generated $131K in revenue in fiscal year 2026. This represents a decrease of 9.0% from the prior year.

EBITDA

-$11.3M

YoY+8.7%

VivoSim Labs Inc's EBITDA was -$11.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.7% from the prior year.

Net Income

-$13.8M

YoY-456.4%

VivoSim Labs Inc reported -$13.8M in net income in fiscal year 2026. This represents a decrease of 456.4% from the prior year.

EPS (Diluted)

-$5.35

VivoSim Labs Inc earned -$5.35 per diluted share (EPS) in fiscal year 2026.

Cash & Balance Sheet

Free Cash Flow

-$10.8M

YoY-14.3%

VivoSim Labs Inc recorded an outflow of $10.8M in free cash flow in fiscal year 2026, representing a cash shortfall after capex. This represents a decrease of 14.3% from the prior year.

Cash & Debt

$5.0M

YoY-55.6%

5Y CAGR-33.1%

10Y CAGR-22.2%

VivoSim Labs Inc held $5.0M in cash as of fiscal year 2026; long-term debt is not reported for that period.

Shares Outstanding

VivoSim Labs Inc had 3M shares outstanding in fiscal year 2026.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Gross Margin

100.0%

YoY+3.5pp

VivoSim Labs Inc's gross margin was 100.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for fiscal year 2026.

Capital Allocation

R&D Spending

$4.2M

YoY-16.6%

5Y CAGR+30.6%

10Y CAGR-13.6%

VivoSim Labs Inc invested $4.2M in research and development in fiscal year 2026. This represents a decrease of 16.6% from the prior year.

Capital Expenditures

YoY-100.0%

VivoSim Labs Inc reported no capital expenditure in fiscal year 2026. This represents a decrease of 100.0% from the prior year.

Share Buybacks

Not reported for fiscal year 2026.

VIVS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

VIVS quarterly income statement

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY12	FY11
Revenue	$112K	$131K-9.0%	$144K+32.1%	$109K-70.5%	$370K-75.3%	$1.5M	$0-100.0%	$2.2M-29.0%	$3.1M-32.8%	$4.6M+8.8%	$4.2M+185.2%	$1.5M+159.7%	$571K+50.7%	$379K	$1.2M+23.5%	$969K
Cost of Revenue	N/A	$0-100.0%	$5K	N/A	N/A	N/A	$0-100.0%	$328K-32.0%	$482K-53.2%	$1.0M+7.7%	$956K	$0	$0	N/A	N/A	$121K
Gross Profit	N/A	$131K-5.8%	$139K	N/A	N/A	N/A	$0-100.0%	$1.9M-28.4%	$2.6M-27.0%	$3.6M+9.1%	$3.3M+120.8%	$1.5M+159.7%	$571K	N/A	N/A	$848K
R&D Expenses	$4.3M	$4.2M-16.6%	$5.0M-8.6%	$5.5M-38.1%	$8.9M+167.6%	$3.3M+201.0%	$1.1M-79.1%	$5.3M-64.2%	$14.8M-17.8%	$18.0M-8.1%	$19.5M+8.5%	$18.0M+39.4%	$12.9M+62.0%	$8.0M	$3.4M+142.0%	$1.4M
SG&A Expenses	$7.1M	$7.4M-3.9%	$7.7M-20.3%	$9.7M+5.2%	$9.2M-4.6%	$9.7M-38.6%	$15.7M-12.9%	$18.1M+19.4%	$15.1M-27.6%	$20.9M-6.3%	$22.3M+0.8%	$22.1M+23.2%	$17.9M+37.5%	$13.1M	$7.1M+308.5%	$1.7M
Operating Income	-$11.3M	-$11.5M+8.9%	-$12.6M+16.4%	-$15.1M+14.9%	-$17.7M-54.5%	-$11.5M+31.8%	-$16.8M+21.6%	-$21.5M+21.3%	-$27.3M+22.7%	-$35.3M+8.6%	-$38.6M+0.2%	-$38.6M-27.5%	-$30.3M-46.7%	-$20.6M	-$9.3M-304.3%	-$2.3M
Interest Expense	$12K	$12K+20.0%	$10K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$1K-92.3%	$13K	$1.1M-47.4%	$2.1M
Income Tax	$5K	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K-33.3%	$3K+50.0%	$2K-91.3%	$23K+666.7%	$3K	$0	$0	N/A	N/A
Net Income	-$12.3M	-$13.8M-456.4%	-$2.5M+83.0%	-$14.7M+15.0%	-$17.3M-50.8%	-$11.4M+32.0%	-$16.8M+10.1%	-$18.7M+29.8%	-$26.6M+23.5%	-$34.8M+9.5%	-$38.4M+0.3%	-$38.6M-28.2%	-$30.1M-16.4%	-$25.8M	-$43.6M-893.7%	-$4.4M
EPS (Diluted)	-$4.47	-$5.35	-$1.70	-$19.25	-$1.98-50.0%	-$1.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00	$0.00

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Revenue	$18K-55.0%	$40K+53.8%	$26K-7.1%	$28K-24.3%	$37K-27.5%	$51K+112.5%	$24K-20.0%	$30K
Cost of Revenue	N/A	$0	$0	$0	$0	$0-100.0%	$2K+100.0%	$1K
Gross Profit	N/A	$40K+53.8%	$26K-7.1%	$28K-24.3%	$37K-27.5%	$51K+131.8%	$22K-24.1%	$29K
R&D Expenses	$1.1M+0.6%	$1.1M-1.3%	$1.1M+23.5%	$923K-7.8%	$1.0M+16.5%	$859K-51.7%	$1.8M+80.9%	$984K
SG&A Expenses	$1.6M-21.7%	$2.1M+28.5%	$1.6M-6.0%	$1.7M-10.8%	$2.0M-16.8%	$2.3M+37.2%	$1.7M+3.4%	$1.7M
Operating Income	-$2.8M+13.4%	-$3.2M-15.9%	-$2.8M-4.4%	-$2.6M+9.6%	-$2.9M+7.6%	-$3.2M+9.1%	-$3.5M-33.0%	-$2.6M
Interest Expense	$4K0.0%	$4K0.0%	$4K	$0-100.0%	$4K-20.0%	$5K0.0%	$5K	$0
Income Tax	$3K	$0	$0-100.0%	$2K	$0	$0	$0	$0
Net Income	-$1.3M+76.8%	-$5.8M-114.2%	-$2.7M-5.7%	-$2.5M+10.5%	-$2.8M-141.5%	$6.9M+298.8%	-$3.4M-35.2%	-$2.5M
EPS (Diluted)	-$0.25	-$2.21-114.6%	-$1.03-5.1%	-$0.98+14.0%	-$1.14+0.9%	-$1.15	-$2.28-35.7%	-$1.68

VIVS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

VIVS quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY12	FY11
Total Assets	$7.4M-49.6%	$14.7M+130.7%	$6.3M-68.7%	$20.3M-39.0%	$33.3M-16.6%	$39.9M+40.4%	$28.4M-30.0%	$40.6M-18.5%	$49.8M-28.0%	$69.2M+2.4%	$67.6M+26.3%	$53.5M+6.6%	$50.2M	$16.7M+1088.7%	$1.4M
Current Assets	$6.6M-45.4%	$12.1M+208.2%	$3.9M-76.9%	$17.0M-42.3%	$29.5M-23.1%	$38.4M+35.6%	$28.3M-26.6%	$38.6M-17.5%	$46.8M-28.2%	$65.1M+2.3%	$63.7M+24.2%	$51.3M+4.3%	$49.2M	$15.9M+1438.9%	$1.0M
Cash & Equivalents	$5.0M-55.6%	$11.3M+289.9%	$2.9M-81.0%	$15.3M-46.6%	$28.7M-23.3%	$37.4M+36.6%	$27.4M-25.0%	$36.5M-16.6%	$43.7M-30.3%	$62.8M+1.1%	$62.1M+23.8%	$50.1M+4.1%	$48.2M	$14.8M+4257.9%	$340K
Inventory	N/A	$0-100.0%	$297K	$0	N/A	N/A	$0-100.0%	$490K-41.8%	$842K+53.1%	$550K+64.7%	$334K+406.1%	$66K+4.8%	$63K	$360K+23.3%	$292K
Accounts Receivable	$32K+6.7%	$30K-9.1%	$33K-78.3%	$152K	$0	$0-100.0%	$111K-77.9%	$503K-43.0%	$883K+36.5%	$647K+149.8%	$259K	$0	N/A	N/A	N/A
Total Liabilities	$8.5M+104.1%	$4.2M+51.3%	$2.7M-44.9%	$5.0M+61.5%	$3.1M+328.2%	$721K-60.2%	$1.8M-58.2%	$4.3M-17.5%	$5.2M-23.1%	$6.8M+26.4%	$5.4M+12.6%	$4.8M+152.0%	$1.9M	$22.1M+579.8%	$3.2M
Current Liabilities	$2.8M-25.5%	$3.7M+100.9%	$1.9M-49.3%	$3.7M+165.4%	$1.4M+91.8%	$721K-60.2%	$1.8M-51.6%	$3.7M-19.8%	$4.7M-22.5%	$6.0M+33.9%	$4.5M-5.7%	$4.8M+151.5%	$1.9M	$22.0M+1014.6%	$2.0M
Total Equity	-$1.1M-110.5%	$10.5M+191.4%	$3.6M-76.5%	$15.3M-49.3%	$30.2M-22.9%	$39.2M+47.2%	$26.6M-26.6%	$36.3M-18.6%	$44.6M-28.5%	$62.4M+0.3%	$62.2M+27.7%	$48.7M+0.9%	$48.3M	-$5.3M-189.0%	-$1.8M
Retained Earnings	-$356.0M-4.0%	-$342.2M-0.7%	-$339.7M-4.5%	-$325.0M-5.6%	-$307.7M-3.9%	-$296.3M-6.0%	-$279.5M-7.2%	-$260.8M-11.4%	-$234.1M-17.5%	-$199.3M-23.9%	-$160.9M-31.5%	-$122.3M	N/A	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Total Assets	$3.8M-47.9%	$7.4M+6.1%	$7.0M-28.1%	$9.7M-19.1%	$12.0M-18.2%	$14.7M+281.1%	$3.8M-43.1%	$6.8M
Current Assets	$3.2M-51.3%	$6.6M+9.7%	$6.0M-20.4%	$7.6M-21.6%	$9.7M-20.2%	$12.1M+477.7%	$2.1M-56.1%	$4.8M
Cash & Equivalents	$1.7M-66.8%	$5.0M+17.2%	$4.3M-35.8%	$6.7M-26.3%	$9.1M-20.0%	$11.3M+874.3%	$1.2M-63.4%	$3.2M
Inventory	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$640K
Accounts Receivable	$29K-9.4%	$32K-3.0%	$33K+3.1%	$32K0.0%	$32K+6.7%	$30K+15.4%	$26K-10.3%	$29K
Total Liabilities	$6.2M-27.0%	$8.5M+236.8%	$2.5M-3.9%	$2.6M+7.4%	$2.4M-41.3%	$4.2M+19.5%	$3.5M+13.2%	$3.1M
Current Liabilities	$1.9M-32.0%	$2.8M+12.5%	$2.5M+1.1%	$2.4M+14.3%	$2.1M-42.7%	$3.7M+27.2%	$2.9M+21.7%	$2.4M
Total Equity	-$2.3M-113.5%	-$1.1M-124.7%	$4.4M-37.1%	$7.1M-25.9%	$9.5M-9.1%	$10.5M+2782.4%	$364K-90.1%	$3.7M
Retained Earnings	-$357.3M-0.4%	-$356.0M-1.6%	-$350.2M-0.8%	-$347.5M-0.7%	-$345.0M-0.8%	-$342.2M+2.0%	-$349.0M-1.0%	-$345.6M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

VIVS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

VIVS quarterly cash flow statement

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY12	FY11
Operating Cash Flow	-$10.1M	-$10.8M-14.4%	-$9.5M+35.4%	-$14.7M-18.1%	-$12.4M-46.8%	-$8.5M+36.6%	-$13.3M+10.5%	-$14.9M+27.0%	-$20.4M+29.4%	-$28.9M+1.1%	-$29.2M+0.6%	-$29.4M-49.8%	-$19.6M-26.0%	-$15.6M	-$9.7M-406.4%	-$1.9M
Capital Expenditures	$23K	$0-100.0%	$13K-69.0%	$42K-89.4%	$396K-3.2%	$409K+1.0%	$405K	$0-100.0%	$79K-65.0%	$226K-83.3%	$1.4M-36.0%	$2.1M+39.4%	$1.5M+447.7%	$277K	$357K+676.1%	$46K
Free Cash Flow	-$10.1M	-$10.8M-14.3%	-$9.5M+35.5%	-$14.7M-14.8%	-$12.8M-44.5%	-$8.9M+35.4%	-$13.7M+7.8%	-$14.9M+27.2%	-$20.5M+29.7%	-$29.1M+4.8%	-$30.5M+3.0%	-$31.5M-49.1%	-$21.1M-33.3%	-$15.8M	-$10.1M-412.8%	-$2.0M
Investing Cash Flow	$71K	$94K-99.0%	$9.0M+1006.0%	$816K+184.5%	-$966K-136.2%	-$409K-4.1%	-$393K-152.6%	$747K+1082.9%	-$76K+74.0%	-$292K	N/A	N/A	N/A	N/A	-$445K-300.9%	-$111K
Financing Cash Flow	$2.6M	$4.4M-49.8%	$8.8M+515.7%	$1.4M	$0-100.0%	$205K-99.1%	$23.8M+383.0%	$4.9M-62.5%	$13.2M+30.1%	$10.1M	N/A	N/A	N/A	N/A	$24.6M+1083.4%	$2.1M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$1K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Operating Cash Flow	-$3.2M-43.6%	-$2.2M+1.5%	-$2.3M+4.5%	-$2.4M+39.6%	-$3.9M-93.6%	-$2.0M-13.0%	-$1.8M+31.8%	-$2.6M
Capital Expenditures	$23K	$0	$0	$0	$0	$0	$0-100.0%	$13K
Free Cash Flow	-$3.2M-44.6%	-$2.2M+1.5%	-$2.3M+4.5%	-$2.4M+39.6%	-$3.9M-93.6%	-$2.0M-13.0%	-$1.8M+32.2%	-$2.7M
Investing Cash Flow	-$23K-124.5%	$94K	$0	$0	$0-100.0%	$9.0M+224925.0%	$4K	$0
Financing Cash Flow	-$118K-104.1%	$2.9M+2540.7%	-$118K	$0-100.0%	$1.7M-47.2%	$3.2M+1574.5%	-$216K+41.8%	-$371K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

VIVS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

VIVS quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY12	FY11
Gross Margin	100.0%+3.5pp	96.5%	N/A	N/A	N/A	N/A	85.1%+0.7pp	84.4%+6.8pp	77.6%+0.2pp	77.4%-22.6pp	100.0%0.0pp	100.0%	N/A	N/A	87.5%
Operating Margin	-8768.7%	-8761.1%	-13840.4%	-4792.2%	-765.3%	N/A	-977.9%	-882.4%	-766.3%	-911.9%	-2605.7%	-5305.9%	-5448.3%	-778.5%	-237.9%
Net Margin	-10567.2%	-1727.8%	-13459.6%	-4664.6%	-763.2%	N/A	-852.0%	-861.7%	-756.1%	-908.9%	-2601.2%	-5268.3%	-6820.1%	-3638.5%	-452.3%
Return on Equity	N/A	-23.7%+383.7pp	-407.4%-294.8pp	-112.6%-74.7pp	-37.9%+5.0pp	-42.9%+27.3pp	-70.3%+3.1pp	-73.4%+4.7pp	-78.1%-16.4pp	-61.7%+0.4pp	-62.0%-0.3pp	-61.8%-8.3pp	-53.5%	N/A	N/A
Return on Assets	-187.4%-170.4pp	-17.0%+214.1pp	-231.1%-146.1pp	-85.0%-50.6pp	-34.4%+7.8pp	-42.1%+23.6pp	-65.8%-0.2pp	-65.6%+4.3pp	-69.8%-14.3pp	-55.6%+1.5pp	-57.1%-0.8pp	-56.2%-4.7pp	-51.5%	-260.0%+51.0pp	-311.1%
Current Ratio	2.38-0.9x	3.25+1.1x	2.12-2.5x	4.64-16.7x	21.35-31.9x	53.26+37.6x	15.65+5.3x	10.32+0.3x	10.04-0.8x	10.83-3.3x	14.18+3.4x	10.77-15.2x	25.97	0.72+0.2x	0.52
Debt-to-Equity	N/A	0.40-0.4x	0.76+0.4x	0.33+0.2x	0.10+0.1x	0.020.0x	0.07-0.1x	0.120.0x	0.120.0x	0.110.0x	0.090.0x	0.10+0.1x	0.04	N/A	N/A
FCF Margin	-8264.9%	-6579.2%	-13481.6%	-3460.5%	-590.8%	N/A	-677.7%	-661.7%	-631.8%	-722.0%	-2122.9%	-3698.4%	-4178.9%	-839.6%	-202.3%

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25
Gross Margin	N/A	100.0%0.0pp	100.0%0.0pp	100.0%0.0pp	100.0%0.0pp	100.0%+8.3pp	91.7%-5.0pp	96.7%
Operating Margin	-15327.8%	-7967.5%	-10576.9%	-9410.7%	-7878.4%	-6184.3%	-14450.0%	-8693.3%
Net Margin	-7433.3%	-14410.0%	-10350.0%	-9089.3%	-7683.8%	13435.3%	-14362.5%	-8496.7%
Return on Equity	N/A	N/A	-60.6%-24.6pp	-36.0%-6.2pp	-29.8%-95.1pp	65.3%+1012.3pp	-947.0%-877.7pp	-69.3%
Return on Assets	-34.8%+43.3pp	-78.0%-39.4pp	-38.7%-12.4pp	-26.3%-2.5pp	-23.7%-70.5pp	46.8%+136.4pp	-89.7%-51.9pp	-37.7%
Current Ratio	1.70-0.7x	2.38-0.1x	2.44-0.7x	3.10-1.4x	4.52+1.3x	3.25+2.5x	0.71-1.3x	1.98
Debt-to-Equity	N/A	N/A	0.57+0.2x	0.37+0.1x	0.26-0.1x	0.40-9.2x	9.56+8.7x	0.84
FCF Margin	-17977.8%	-5595.0%	-8734.6%	-8492.9%	-10648.7%	-3990.2%	-7504.2%	-8850.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Matinas Biopharm MTNB

$2.9M

IMV Inc IMV

$9.8M

Essa Pharma EPIX

$9.5M

Processa Pharmaceuticals Inc PCSA

$5.8M

Cyclacel Phar Pr CYCCP

$9.6M

Where VivoSim Labs Inc Ranks

Frequently Asked Questions

What is VivoSim Labs Inc's annual revenue?

VivoSim Labs Inc (VIVS) reported $131K in total revenue for fiscal year 2026. This represents a -9.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is VivoSim Labs Inc's revenue growing?

VivoSim Labs Inc (VIVS) revenue declined by 9.0% year-over-year, from $144K to $131K in fiscal year 2026.

Is VivoSim Labs Inc profitable?

No, VivoSim Labs Inc (VIVS) reported a net income of -$13.8M in fiscal year 2026.

What is VivoSim Labs Inc's EBITDA?

VivoSim Labs Inc (VIVS) had EBITDA of -$11.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is VivoSim Labs Inc's gross margin?

VivoSim Labs Inc (VIVS) had a gross margin of 100.0% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is VivoSim Labs Inc's free cash flow?

VivoSim Labs Inc (VIVS) recorded an outflow of $10.8M in free cash flow during fiscal year 2026. This represents a -14.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is VivoSim Labs Inc's operating cash flow?

VivoSim Labs Inc (VIVS) recorded an outflow of $10.8M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are VivoSim Labs Inc's total assets?

VivoSim Labs Inc (VIVS) had $7.4M in total assets as of fiscal year 2026, including both current and long-term assets.

What are VivoSim Labs Inc's capital expenditures?

VivoSim Labs Inc (VIVS) reported no capital expenditure during fiscal year 2026.

How much does VivoSim Labs Inc spend on research and development?

VivoSim Labs Inc (VIVS) invested $4.2M in research and development during fiscal year 2026.

How many shares does VivoSim Labs Inc have outstanding?

VivoSim Labs Inc (VIVS) had 3M shares outstanding as of fiscal year 2026.

What is VivoSim Labs Inc's current ratio?

VivoSim Labs Inc (VIVS) had a current ratio of 2.38 as of fiscal year 2026, which is generally considered healthy.

What is VivoSim Labs Inc's return on assets (ROA)?

VivoSim Labs Inc (VIVS) had a return on assets of -187.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

How does VivoSim Labs Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, VivoSim Labs Inc (VIVS) held $5.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is VivoSim Labs Inc's debt-to-equity ratio negative or not reported?

VivoSim Labs Inc (VIVS) has negative shareholder equity of -$1.1M as of fiscal year 2026, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is VivoSim Labs Inc's Altman Z-Score?

VivoSim Labs Inc (VIVS) has an Altman Z-Score of -71.69, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is VivoSim Labs Inc's Piotroski F-Score?

VivoSim Labs Inc (VIVS) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are VivoSim Labs Inc's earnings high quality?

VivoSim Labs Inc (VIVS) reported a net loss of $13.8M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can VivoSim Labs Inc cover its interest payments?

VivoSim Labs Inc (VIVS) reported an operating loss of $11.5M against $12K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.